Oraya Therapeutics Completes Enrollment In Pioneering Sham-Controlled Study Of Radiation Therapy For Wet AMD

Oraya Therapeutics, Inc. today announced that it has completed enrollment of its INTREPID clinical trial in Europe. The study is the first sham-controlled, double-masked trial to evaluate the effectiveness and safety of radiation therapy in conjunction with standard of care anti-VEGF injections for the treatment of wet age-related macular degeneration (AMD)...